Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Dermatologic 1Breast 1

Conditions

Melanoma 6Diarrhea 2Colitis 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Non Small Cell Lung Cancer Metastatic 1Lung Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 28Cyclophosphamide 14Nivolumab 13Paclitaxel 7fludarabine 6Specimen Handling 5aldesleukin 4Taxes 4Ipilimumab 4Interleukin-2 4Gemcitabine 4Drug Therapy 4Docetaxel 4Carboplatin 4Bevacizumab 4poly ICLC 3liposomal doxorubicin 3epacadostat 3cobimetinib 3cemiplimab 3Magnetic Resonance Spectroscopy 3Injections 3Cisplatin 3veliparib 2ulixertinib 2sargramostim 2pertuzumab 2pegilodecakin 2pazopanib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × Fecal Microbiota Transplantation × Dermatologic × Clear all
NCT04038619 2026-03-20

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

M.D. Anderson Cancer Center

Phase 1 Recruiting
40 enrolled
BreastDermatologicGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colitis, Diarrhea, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Urogenital Neoplasms, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡